Derma Sciences, Inc (DSCI)

[BioSpecialist]

DSCI was a $200+ stock a few years ago ...

and it has really good chance to move back up to that level with our 1.5 Mil low float .


DSC127 THE MULTIPLE BLOCKBUSTER IS THE REASON WHY WE COULD SEE THE OLD HIGHS AGAIN .MAJOR PHASE 2 RESULTS COMING THIS OR NEXT WEEK AND THE COMPANY IS VERY OPTIMISTIC ABOUT THE RESULTS .A POTENTIAL PARTNERSHIP FOR DSC127 COULD BRING UPFRONT PAYMENTS WHICH WILL BE MUCH HIGHER THAN CURRENT MARKET CAP .AGAIN THIS IS A PURE GOLDMINE !!! GL


KEY PRODUCT UNDER DEVELOPMENT

DSDSC127 (angiotensin analog)

Novel angiotensin analog for use in wound healing and scar reduction. Successfully completed a phase I trial in 4Q07, and presently undergoing phase II trials to assess safety and efficacy of DSC127 on healing diabetic ulcers. Results from the phase II trials are expected in 4Q10.

* "Blockbuster" potential - with applications in the following markets:

o $10 billion chronic wound market
o $8 billion scar prevention/reduction market
o $6 billion burn market
o $6 billion radiation and other wound markets

* Limited competition - Systagenix's Regranex is the only FDA-approved drug for wound healing. (Systegenix is formerly Johnson & Johnson's Chronic Wound Care division.)
o Regranex has a black box warning and has achieved sales exceeding $100M per year




Derma Sciences presents a unique opportunity in the micro-cap biomed space since it has a core business focused on would care which generates revenue and operating cash flow to fund the Phase 2 clinical development for a treatment (DC127) that targets a prescription drug market that is about 5X the Company’s current market cap (based on Regranex sales of $150M). In addition, pre-clinical data suggests DC127 may offer both safety and efficacy advantages over Regranex and the licensing deal by Shire for a scar prevention treatment that included a $75M up-front payment suggests Derma Sciences has the potential to secure a licensing deal that could include an up-front cash payment in excess of its current market cap of around $30M.